**RESEARCH ARTICLE**

**Bordetella pertussis** entry into respiratory epithelial cells and intracellular survival

Yanina Lamberti, Juan Gorgojo, Cintia Massillo & Maria E. Rodriguez

CINDEFI (UNLP CONICET La Plata), Facultad de Ciencias Exactas, Universidad Nacional de La Plata, La Plata, Argentina

This article describes entry and intracellular survival of *Bordetella pertussis* in a human lung epithelial cell line. This is a poorly understood property of this bacterial pathogen and represents a possible mechanism by which it might evade the host immune system.

**Keywords**

*Bordetella pertussis*; respiratory epithelial cells; bacterial persistence.

**Abstract**

*Bordetella pertussis* is the causative agent of pertussis, aka whooping cough. Although generally considered an extracellular pathogen, this bacterium has been found inside respiratory epithelial cells, which might represent a survival strategy inside the host. Relatively little is known, however, about the mechanism of internalization and the fate of *B. pertussis* in the epithelia. We show here that *B. pertussis* is able to enter those cells by a mechanism dependent on microtubule assembly, lipid raft integrity, and the activation of a tyrosine-kinase-mediated signaling. Once inside the cell, a significant proportion of the intracellular bacteria evade phagolysosomal fusion and remain viable in nonacidic lysosome-associated membrane-protein-1-negative compartments. In addition, intracellular *B. pertussis* was found able to repopulate the extracellular environment after complete elimination of the extracellular bacteria with polymyxin B. Taken together, these data suggest that *B. pertussis* is able to survive within respiratory epithelial cells and by this means potentially contribute to host immune system evasion.

**Introduction**

*Bordetella pertussis* is a strictly human pathogen and the main causative agent of whooping cough, aka pertussis. Despite a high vaccination cover, pertussis remains endemic within the world population. The persistence of pertussis in countries with highly vaccinated populations has been attributed to various causes including suboptimal vaccines, a waning immunity, and pathogen adaptation (He & Mertsola, 2008; Berbers et al., 2009; Mooi et al., 2013). *Bordetella pertussis* colonizes the mucosa of the respiratory tract, where the bacterium interacts with epithelial cells and local immune surveillance cells. Although certain potential contributors to colonization have been described (de Gouw et al., 2011), the mechanisms that allow this pathogen to evade immune clearance, causing a highly contagious and prolonged respiratory disease, are still under investigation.

Although *B. pertussis* is usually regarded as a noninvasive pathogen, a number of studies suggest that the bacterium is able to enter into and eventually survive inside the cells (Higgs et al., 2012). *Bordetella pertussis* have been found within pulmonary alveolar macrophages from infants and children with confirmed *B. pertussis* pneumonia (Paddock et al., 2008) and inside alveolar macrophages of HIV-infected children (Bromberg et al., 1991). Animal infection models and studies using human monocytes in culture have indicated that *B. pertussis* can enter and survive inside those cells (Friedman et al., 1992; Hellwig et al., 1999; Vandebriel et al., 2003). We recently found that *B. pertussis* not only is able to survive inside human macrophages, but also replicates in nonacidic compartments having the characteristics of early endosomes (Lamberti et al., 2010). These data suggest that the pathogen has evolved mechanisms to evade phagolysosomal fusion and survive intracellularly, so as to eventually increase the opportunity of spreading to new hosts.

In the present study, we investigated whether *B. pertussis* is also able to reside within epithelial respiratory cells and proliferate from there. Previous studies in culture revealed the presence of *B. pertussis* inside epithelial cells (Bassinet et al., 2000; Ishibashi et al., 2001; Guerard et al., 2005). Moreover, *B. pertussis* has been found inside ciliated respiratory epithelial cells in children with pneumonia...
Bacteria to survive intracellularly. Epithelial respiratory cells and assessing the ability of the *B. pertussis* mechanisms underlying the entry of internalization. The present study aimed at elucidating the 2000; Ishibashi into epithelial cells (Ewanowich 2001), thus suggesting a connection by Lamberti et al. (Paddock 2009), with minor modifications. Stated in brief, A549 cells were seeded on glass coverslips in 24-well tissue culture plates (Nunc, Roskilde, Denmark) and cultured to 70% confluence. The monolayers were then washed twice with sterile phosphate-buffered saline (PBS) and infected with either *B. pertussis* or GFP-*B. pertussis* in 0.2% bovine serum albumin (BSA; DMEM): DMEM plus 0.2% (w/v) BSA (Sigma) at a multiplicity of infection (MOI) of 150 bacteria per cell unless otherwise stated. To facilitate bacterial interaction with the epithelial cells, the plates were centrifuged for 5 min at 640 g. After 2 h at 37 °C in 5% (v/v) CO₂, the infected cells were washed four times with PBS to remove nonadherent bacteria. For the determination of bacterial attachment, the cells were fixed with 3% (v/v) paraformaldehyde. The number of adherent GFP-bacteria per cell was then determined by microscopical examination of 20 randomly selected fields. In representative samples, the viability of adherent bacteria was evaluated by means of the LIVE/DEAD BacLight kit (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. For invasion assays, after the washing steps, the cells were incubated for another 12 h at 37 °C in 0.2% BSA (DMEM) unless otherwise stated. The number of intracellular bacteria was finally determined both by double staining immunofluorescence microscopy and by polymyxin B protection assays as described below.

For immunofluorescence staining of intracellular and extracellular bacteria, surface-bound bacteria were detected by incubation of the A549 cells with rabbit anti-*B. pertussis* serum for 1 h at 4 °C, followed by incubation with CY3-conjugated goat *F(ab′)₂* fragments of anti-rabbit IgG for another 1 h at 4 °C. To determine the number of intracellular bacteria, after two washes of the cultures with 0.2% BSA (PBS), the cells were permeabilized by incubation with PBS containing 0.1% (w/v) saponin (Sigma) and 0.2% (w/v) BSA anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA), and FITC-conjugated goat *F(ab′)₂* fragments of anti-rabbit IgG (Jackson ImmunoResearch). Polyclonal rabbit anti-*B. pertussis* antiserum was obtained as described elsewhere (Hellwig et al., 2001).

**Cells and growth conditions**

The human alveolar epithelium cell line A549 (human lung type-II pneumocyte; American Type Culture Collection CCL185, Rockville, MD) was cultured in 10% fetal bovine serum (FBS; DMEM); Dulbecco's modified Eagle's Minimal Essential Medium (DMEM) supplemented with 10% (v/v) FBS, 100 U mL⁻¹ penicillin, and 100 mg mL⁻¹ streptomycin (Sigma, St. Louis, MO) at 37 °C in 5% (v/v) CO₂. Routine subcultures for A549 pneumocytes were performed at 1 : 3 split ratios by incubation with 0.05% (w/v) trypsin plus 0.02% (w/v) ethylenediaminetetraacetic acid for 5 min at 37 °C. For infection assays, the epithelial cells were cultured to 70% confluence.

**Infection assays**

Infection assays were performed as described in the study by Lamberti et al. (2009), with minor modifications. Stated in brief, A549 cells were seeded on glass coverslips in 24-well tissue culture plates (Nunc, Roskilde, Denmark) and cultured to 70% confluence. The monolayers were then washed twice with sterile phosphate-buffered saline (PBS) and infected with either *B. pertussis* or GFP-*B. pertussis* in 0.2% bovine serum albumin (BSA; DMEM): DMEM plus 0.2% (w/v) BSA (Sigma) at a multiplicity of infection (MOI) of 150 bacteria per cell unless otherwise stated. To facilitate bacterial interaction with the epithelial cells, the plates were centrifuged for 5 min at 640 g. After 2 h at 37 °C in 5% (v/v) CO₂, the infected cells were washed four times with PBS to remove nonadherent bacteria. For the determination of bacterial attachment, the cells were fixed with 3% (v/v) paraformaldehyde. The number of adherent GFP-bacteria per cell was then determined by microscopical examination of 20 randomly selected fields. In representative samples, the viability of adherent bacteria was evaluated by means of the LIVE/DEAD BacLight kit (Invitrogen, Carlsbad, CA) according to the manufacturer's instructions. For invasion assays, after the washing steps, the cells were incubated for another 12 h at 37 °C in 0.2% BSA (DMEM) unless otherwise stated. The number of intracellular bacteria was finally determined both by double staining immunofluorescence microscopy and by polymyxin B protection assays as described below.

**Antibodies**

The following antibodies were used: mouse monoclonal antibody against human lysososome-associated membrane protein 1 (LAMP1; BD Biosciences Pharmingen, San Diego, CA), FITC-conjugated mouse monoclonal antibody against early endosome antigen 1 (EEA-1; BD Biosciences Pharmingen), CY3-conjugated goat *F(ab′)₂* fragments of anti-mouse immunoglobulin G (IgG; Molecular Probes, Eugene, OR), CY3-conjugated goat *F(ab′)₂* fragments of anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA), and FITC-conjugated goat *F(ab′)₂* fragments of anti-rabbit IgG (Jackson ImmunoResearch). Polyclonal rabbit anti-*B. pertussis* antiserum was obtained as described elsewhere (Hellwig et al., 2001).

**Cells and growth conditions**

The human alveolar epithelium cell line A549 (human lung type-II pneumocyte; American Type Culture Collection CCL185, Rockville, MD) was cultured in 10% fetal bovine serum (FBS; DMEM); Dulbecco’s modified Eagle’s Minimal Essential Medium (DMEM) supplemented with 10% (v/v) FBS, 100 U mL⁻¹ penicillin, and 100 mg mL⁻¹ streptomycin (Sigma, St. Louis, MO) at 37 °C in 5% (v/v) CO₂. Routine subcultures for A549 pneumocytes were performed at 1 : 3 split ratios by incubation with 0.05% (w/v) trypsin plus 0.02% (w/v) ethylenediaminetetraacetic acid for 5 min at 37 °C. For infection assays, the epithelial cells were cultured to 70% confluence.

**Infection assays**

Infection assays were performed as described in the study by Lamberti et al. (2009), with minor modifications. Stated in brief, A549 cells were seeded on glass coverslips in 24-well tissue culture plates (Nunc, Roskilde, Denmark) and cultured to 70% confluence. The monolayers were then washed twice with sterile phosphate-buffered saline (PBS) and infected with either *B. pertussis* or GFP-*B. pertussis* in 0.2% bovine serum albumin (BSA; DMEM): DMEM plus 0.2% (w/v) BSA (Sigma) at a multiplicity of infection (MOI) of 150 bacteria per cell unless otherwise stated. To facilitate bacterial interaction with the epithelial cells, the plates were centrifuged for 5 min at 640 g. After 2 h at 37 °C in 5% (v/v) CO₂, the infected cells were washed four times with PBS to remove nonadherent bacteria. For the determination of bacterial attachment, the cells were fixed with 3% (v/v) paraformaldehyde. The number of adherent GFP-bacteria per cell was then determined by microscopical examination of 20 randomly selected fields. In representative samples, the viability of adherent bacteria was evaluated by means of the LIVE/DEAD BacLight kit (Invitrogen, Carlsbad, CA) according to the manufacturer’s instructions. For invasion assays, after the washing steps, the cells were incubated for another 12 h at 37 °C in 0.2% BSA (DMEM) unless otherwise stated. The number of intracellular bacteria was finally determined both by double staining immunofluorescence microscopy and by polymyxin B protection assays as described below.

**Antibodies**

The following antibodies were used: mouse monoclonal antibody against human lysosome-associated membrane protein 1 (LAMP1; BD Biosciences Pharmingen, San Diego, CA), FITC-conjugated mouse monoclonal antibody against early endosome antigen 1 (EEA-1; BD Biosciences Pharmingen), CY3-conjugated goat *F(ab′)₂* fragments of anti-mouse immunoglobulin G (IgG; Molecular Probes, Eugene, OR), CY3-conjugated goat *F(ab′)₂* fragments of anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA), and FITC-conjugated goat *F(ab′)₂* fragments of anti-rabbit IgG (Jackson ImmunoResearch). Polyclonal rabbit anti-*B. pertussis* antiserum was obtained as described elsewhere (Hellwig et al., 2001).

**Materials and methods**

**Bacterial strain and growth conditions**

*Bordetella pertussis* strain B213, a streptomycin-resistant derivative of Tohama I, was used in this study. In some experiments, B213 transformed with plasmid pCW505 (Weingart et al., 1999; kindly supplied by Dr Alison Weiss, Cincinnati, OH) – which induces cytoplasmic expression of green fluorescent protein (GFP) without affecting growth or antigen expression (Weingart et al., 1999) – was used. Bacteria were stored at –70 °C and recovered by growth on Bordet Gengou agar (BGA) plates supplemented with 15% (v/v) defibrinated sheep blood (bBGA) at 35 °C for 3 days. Virulent bacteria were subsequently plated on bBGA, cultured for 20 h at 35 °C, and thereafter used in infection assays.

**Antibodies**

The following antibodies were used: mouse monoclonal antibody against human lysosome-associated membrane protein 1 (LAMP1; BD Biosciences Pharmingen, San Diego, CA), FITC-conjugated mouse monoclonal antibody against early endosome antigen 1 (EEA-1; BD Biosciences Pharmingen), CY3-conjugated goat *F(ab′)₂* fragments of anti-mouse immunoglobulin G (IgG; Molecular Probes, Eugene, OR), CY3-conjugated goat *F(ab′)₂* fragments of anti-rabbit IgG (Jackson ImmunoResearch, West Grove, PA), and FITC-conjugated goat *F(ab′)₂* fragments of anti-rabbit IgG (Jackson ImmunoResearch). Polyclonal rabbit anti-*B. pertussis* antiserum was obtained as described elsewhere (Hellwig et al., 2001).
for 30 min, followed by a further incubation for 1 h at 4 °C with rabbit anti-B. pertussis serum in the presence of 0.1% (w/v) saponin and 0.2% (w/v) BSA. After three further washes, the cells were incubated with FITC-conjugated F(ab′)2 fragments of goat anti-rabbit IgG for 1 h at 4 °C. The labeling of intracellular bacteria with FITC-conjugated antibodies was performed to minimize the loss of readout sensitivity resulting from the quenching of GFP fluorescence after internalization. After washing, samples were analyzed by fluorescence microscopy under a confocal laser scanning microscope (model TCS SP5; Leica, Wetzlar, Germany). The number of extracellular (red and green) and intracellular (green) bacteria was evaluated by examination of at least 100 eukaryotic cells.

For the polymyxin B protection assays, cells were incubated for 1 h at 37 °C in 10% FBS (DMEM) supplemented with 100 μg mL−1 of polymyxin B sulfate (Sigma) – an antibiotic that cannot penetrate mammalian cells (Lee et al., 1990) – to kill the remaining extracellular bacteria. After three washing steps, infected monolayers of the A549 cells were incubated with trypsin to detach the cells from the well, and the number of viable eukaryotic cells was determined by trypan blue dye exclusion. Next, the cells were lysed with 0.1% (w/v) saponin in sterile water, and serial dilutions of the lysates were rapidly plated onto bBGA plates to enumerate colony-forming units (CFU). Viable intracellular bacteria were expressed as the number of viable bacteria per epithelial cell. Control experiments to assess the efficacy of antibiotic bactericidal activity were performed in parallel, as stated here in brief: Samples of 5 × 108 bacteria were incubated with polymyxin B in 10% FBS (DMEM) for 1 h at 37 °C and then plated on bBGA. This antibiotic exposure resulted in a 99.999% decrease in CFU.

When indicated, cells were preincubated for 1 h with cytochalasin D (5 μg mL−1), nocodazole (10 μM), or genistein (100 μM). The drugs (purchased from Sigma) were maintained throughout the experiment. In separate experiments, cells were pretreated with 10 mM methyl-β-cyclodextrin (MβCD; Sigma) plus 5 μg mL−1 of lovastatin (Sigma) for 15 min at 37 °C as described previously (Lamberti et al., 2009) before infection with B. pertussis. In these experiments, lovastatin (5 μg mL−1) was maintained throughout the infection period. At the concentrations used, none of the treatments affected epithelial cell viability as determined by trypan blue dye exclusion. Moreover, the drugs did not affect bacterial viability or growth rate under the conditions tested.

To determine intracellular viability over time, in selected experiments after polymyxin B (100 μg mL−1) treatment, the cells were washed to remove the antibiotic and further incubated with 10% FBS (DMEM), 1% FBS (DMEM), or 0.2% BSA (DMEM), with or without the addition of polymyxin B (5 μg mL−1), for a further 0, 24, and 48 h. The viable intracellular bacteria per epithelial cell were then determined by CFU counts as described above. Informative control experiments demonstrated that polymyxin B treatment did not affect A549 cell viability over the time of the experiment, as determined by trypan blue dye exclusion. Likewise, additional controls demonstrated that bacterial infection did not induce A549 cell lysis as compared to uninfected cells during the experiment, as determined by trypan blue dye exclusion.

Confocal laser scanning microscopy analysis
A549 cells were seeded onto glass coverslips. For studies of bacterial colocalization with filamentous actin, the cells were infected for 2 h with B. pertussis (MOI 150), washed, and incubated for a further 12 h at 37 °C. For F-actin labeling, the cells were then fixed with 3% paraformaldehyde at room temperature for 15 min and incubated with FITC-conjugated phalloidin (Sigma) diluted 1 : 100. To label B. pertussis, the cells were first permeabilized by incubation with PBS containing 0.1% saponin and 0.2% BSA for 30 min and then incubated for 1 h with rabbit anti-B. pertussis serum in the presence of 0.1% saponin and 0.2% BSA. After three washes, the cells were incubated for 1 h at 4 °C with CY3-conjugated F(ab′)2 fragments of goat anti-rabbit IgG in the presence of 0.1% saponin and 0.2% BSA, washed, and analyzed by confocal microscopy as described below.

For colocalization studies of bacteria with the LAMP1, the EEA1, or the LysoTracker™ probe, A549 cells were infected for 2 h with B. pertussis at an MOI of 150 unless otherwise stated, washed, and incubated for a further 12 h at 37 °C. Extracellular bacteria were then killed with polymyxin B (100 μg mL−1) as described above, and the cells were further incubated in 10% FBS (DMEM) containing 5 μg mL−1 of polymyxin B for 0, 24, and 48 h. The cells were finally incubated with or without 200 nM LysoTracker™ DND-99 (Molecular Probes) for 5 min at 37 °C before fixation with paraformaldehyde. Those samples that were not incubated with the LysoTracker™ stain were washed twice with PBS and incubated for 10 min at room temperature with PBS containing 50 mM NaH2CO3. After two washes, cells were incubated for 30 min with PBS containing 0.1% saponin and 0.2% BSA. Next, the cells were incubated for 1 h at 4 °C with either mouse anti-human LAMP-1 monoclonal antibodies plus rabbit anti-B. pertussis serum or FITC-conjugated mouse anti-human EEA1 monoclonal antibodies plus rabbit anti-B. pertussis serum in the presence of 0.1% saponin and 0.2% BSA. The cells were then washed three times with 0.1% saponin and 0.2% BSA. For colocalization studies with LAMP1, the cells were incubated (1 h) with FITC-conjugated F(ab′)2 fragments of goat anti-rabbit IgG and CY3-conjugated F(ab′)2 fragments of goat anti-mouse IgG (1 h at 4 °C). For colocalization studies with EEA1, the cells were incubated with CY3-conjugated F(ab′)2 fragments of goat anti-rabbit IgG. Isotype controls were run in parallel. To avoid cytoplasmic binding of antibodies to FcγR, all incubations were performed in the presence of 25% (v/v) heat-inactivated human serum.

Microscopical analyses were performed with a confocal laser scanning microscope (model TCS SP5; Leica). In all experiments, a minimum of 100 eukaryotic cells were examined per sample.
Statistical analysis

The Student’s t-test (confidence level, 95%) or ANOVA was used for statistical evaluation of the data. The significance of the differences between the mean values of the data as evaluated by ANOVA was determined by means of the least significant difference test at a confidence level of 95%. The results are shown as means ± SD.

Results

Entry of B. pertussis into A549 cells

The ability of B. pertussis to invade A549 cells and survive intracellularly was evaluated through the use of polymyxin B protection assays. To that end, B. pertussis was incubated with the epithelial cells at an MOI of 150 for 2 h at 37 °C, washed to remove nonadherent bacteria, and further incubated for 0, 3, 12, or 24 h before polymyxin B treatment. The number of viable intracellular bacteria was quantified by CFU counts. Figure 1 shows an increase in the number of viable intracellular bacteria as the incubation time progressed, indicating that after initial attachment, the entry of the bacteria proceeded for at least 24 h. Double fluorescence staining of intracellular and extracellular bacteria further revealed that more than 90% of the epithelial cells were infected (data not shown). The invasion rates at lower MOIs (100, 50, and 10 bacteria per cell) were also tested. As expected, at lower MOIs, a decrease in the initial bacterial attachment occurred along with a concomitant reduction in the number of viable intracellular B. pertussis. At an MOI as low as 10, however, after 2 h of infection, a significant number of viable bacteria were already detected in the cells (10 ± 4 bacteria per 100 cells).

To have a number of intracellular bacteria that enabled a proper readout, subsequent studies were carried out at an MOI of 150 with the infection proceeding for 12 h at 37 °C unless otherwise stated.

Involvement of host microtubular network, lipid raft domains, and tyrosine kinase activity in the entry of B. pertussis into A549 cells

Bacterial entry usually requires host cytoskeleton rearrangements (Alonso & Garcia-del Portillo, 2004) and normally involves microfilaments (Dramsi & Cossart, 1998; Chu & Lu, 2005) or microtubules alone (Oelschläger et al., 1993; Morey et al., 2011) or both microfilaments and microtubules (Richardson & Sadow, 1988; Tsuda et al., 2005; Dhakal & Mulvey, 2009). To determine the contribution of microfilaments during B. pertussis invasion, the spatial association of B. pertussis with the actin of the host cytoskeleton was analyzed by confocal microscopy after 12 h of infection. Figure 2 shows F-actin-rich structures colocalizing with adherent bacteria (Fig. 2, surface focal plane). In contrast to the adherence-associated rearrangement of actin, intracellular bacteria were not associated with the host filamentous actin (Fig. 2, middle focal plane). To further evaluate the role of actin polymerization in B. pertussis entry, we preincubated A549 cells with cytochalasin D, an inhibitor of actin polymerization that disrupts microfilaments, and then determined bacterial internalization by the polymyxin B protection assay. Treatment of A549 cells with cytochalasin D did not decrease the number of intracellular bacteria (Fig. 3), indicating that the observed mobilization of F-actin around adhering B. pertussis is not implicated in the bacterial entry into A549 cells. We then evaluated whether microtubular polymerization might be involved in B. pertussis invasion. To this end, before infection, the A549 cells were treated with nocodazole, a microtubule-depolymerizing agent, and upon infection, bacterial invasion was once again determined by the polymyxin B protection assay. Bordetella pertussis entry decreased by approximately 62% upon the addition of nocodazole (Fig. 3), suggesting that B. pertussis entry involves the assembly of the host microtubular network. That nocodazole affected neither bacterial attachment to A549 cells nor cell viability, as determined by trypan blue staining (data not shown), ruled out those possible trivial explanations.

A previous report had shown that lipid rafts localized around adhering B. pertussis during attachment (Lamberti et al., 2009). These domains were later found to be involved in the invasion by and intracellular survival of other bacterial pathogens (Hartlova et al., 2010). To investigate more precisely the role of lipid rafts in the entry of B. pertussis into epithelial cells, A549 cells were incubated with MßCD—a compound that disrupts cholesterol-rich domains by extracting the sterol—and then examined for bacterial attachment at 2 h and bacterial invasion at 12 h postinfection. The experiments were performed in the presence ofLovastatin to inhibit de novo cholesterol synthesis. The number of intracellular bacteria was determined by fluorescent staining of extra- and intracellular bacteria in combination with the polymyxin B protection assay. Figure 4(a) shows representative images of the epithelial cells incubated with or without MßCD before infection. In agreement
with previous results (Lamberti et al., 2009), the attachment of *B. pertussis* to the epithelial cells was significantly diminished by MßCD treatment of the cells: A 60 ± 4% reduction in bacterial adherence was observed in MßCD-treated cells as compared with untreated controls. To evaluate the effect of MßCD on *B. pertussis* entry independently of the reduction in bacterial attachment, the extent of bacterial internalization was calculated as a percentage of the number of surface-associated bacteria determined at 2 h postinfection. Figure 4(b) shows that cholesterol depletion led to a significant decrease in bacterial entry, indicating that apart from bacterial attachment, lipid rafts are involved in the entry of *B. pertussis*. A similar reduction in the number of viable intracellular bacteria was observed in the polymyxin B protection assays (data not shown).

We next studied the contribution of tyrosine kinases to *B. pertussis* entry into the pulmonary epithelial cells. Tyrosine kinases had been found to be crucial for the lipid raft-dependent invasion processes of other pathogens (Zaas et al., 2005b; Schulz et al., 2012). Accordingly, A549 cells were treated with genistein – a tyrosine kinase inhibitor generally recognized as a selective blocker of raft-dependent endocytic pathways (Lajoie & Nabi, 2007) – and *B. pertussis* invasion was subsequently determined by the polymyxin B protection assay. Treatment of A549 cells with this drug did not affect the bacterial attachment level (data not shown) but significantly decreased the number of intracellular *B. pertussis* (Fig. 5), suggesting that tyrosine kinase activity might participate in the dependence of bacterial entry on lipid rafts.

*Bordetella pertussis* survival inside respiratory epithelial cells

Host cell invasion and intracellular survival is an effective immune evasion strategy for many pathogenic bacteria (Haglund & Welch, 2011). We therefore evaluated the intracellular fate of *B. pertussis* after entering into the respiratory epithelial cells. To this end, A549 cells were

---

**Fig. 2** Confocal microscopy analysis of *Bordetella pertussis* association with host actin cytoskeleton. A549 cells were infected with *B. pertussis* at an MOI of 150 for 2 h at 37 °C, washed, and incubated for a further 12 h. Samples were fixed and stained for F-actin (green) and *B. pertussis* (red). Images were obtained in various focal planes by scanning from the apical to the basal surfaces of the eukaryotic cell. Confocal images of a surface focal plane and a middle focal plane of the same cell are shown. The colocalization of adherent bacteria and actin filament is indicated by arrows. The lack of colocalization of intracellular bacteria and actin filament is indicated by arrowheads. Representatives of one of three independent experiments are shown.

**Fig. 3** Requirement of host cell microtubule polymerization for *Bordetella pertussis* invasion. A549 cells treated without inhibitors (control) or with cytochalasin D (5 μg mL⁻¹) or nocodazole (10 μM) for 1 h at 37 °C were incubated with *B. pertussis* (MOI 150) for 2 h at 37 °C, washed, and incubated for a further 12 h in the presence of the respective drug. The number of live intracellular bacteria was determined by the polymyxin B protection assay. The figure shows the mean values ± SD of two independent experiments each performed in triplicate. The number of viable intracellular bacteria in nocodazole-treated cells was significantly different from the number of viable intracellular bacteria in nontreated or cytochalasin D-treated cells (*P < 0.05).
infected with *B. pertussis* for 12 h and further treated with polymyxin B to kill extracellular bacteria. The cells were incubated for an additional 0, 24, or 48 h in the presence of polymyxin B (5 μg mL⁻¹). The number of viable intracellular bacteria was evaluated at different times by CFU counts. To estimate the percentage of intracellular *B. pertussis* that were able to survive, the number of bacteria inside the cells was determined in parallel by two-color fluorescence microscopy, which enabled the discrimination between extra- and intracellular bacteria. Figure 6(a) shows that immediately after polymyxin B treatment (time = 0 h), 3.82 ± 0.55 bacteria per cell were alive (48 ± 9% of the intracellular bacteria). Importantly, about 100% of the bacteria associated with the epithelial cells had been alive before polymyxin B treatment, as determined by live-dead differential staining (data not shown). To investigate the subcellular localization of the internalized *B. pertussis*, A549 cells were stained with the late endosomal/lysosomal marker LAMP1. Figure 6(b) shows that 54 ± 7% of the intracellular bacteria were found in LAMP1-negative phagosomes immediately after polymyxin B treatment (Fig. 6b, 0 h). As time progressed, the number of viable intracellular bacteria decreased (Fig. 6a), while the number of *B. pertussis*-containing phagosomes positive for LAMP1 increased (Fig. 6b and c). At 24 h after polymyxin B treatment, c. 28% of the intracellular bacteria (1.57 ± 0.36 of 5.63 ± 6.36 bacteria) were found not colocalized with LAMP1 label, and at that time, the CFU counts indicated a total of 1.4 ± 0.18 viable bacteria per cell. A similar correspondence between the number of LAMP1-negative bacteria and CFU counts was observed in samples taken at 48 h (Fig. 6). Colocalization studies with LysoTracker®TM, an acidotropic fluorescent dye that accumulates in acidic organelles, showed similar results. A lack of colocalization of *B. pertussis* with LysoTracker®TM was observed in 3.6 ± 0.6, 1.5 ± 0.4, and 0.7 ± 0.3 bacteria per cell at 0, 24, and 48 h, respectively, after polymyxin B treatment. To further investigate the intracellular localization of the bacteria that were not found within late endosomal or lysosomal compartments, A549 cells were stained with the early endosomal marker EEA1. Colocalization studies indicated that about 20% of the intracellular *B. pertussis* were located in EEA1-positive compartments 48 h after polymyxin B treatment (Fig. 7). Relevant too is the observation that this intracellular trafficking was also observed in assays performed at the lowest MOI tested (an MOI of 10; data not shown).
Release of viable intracellular *B. pertussis* from the cells into the medium

Because both cell entry and exit are critical steps in the cell cycles of intracellular pathogens (Hybiske & Stephens, 2007), we next examined whether intracellular *B. pertussis* was released in a viable state into the extracellular medium.

To investigate this question, epithelial cell infection was carried out as described above, but after the initial killing of the extracellular bacteria with polymyxin B (100 μg mL⁻¹), cells were incubated with either 10% FBS (DMEM) plus polymyxin B (5 μg mL⁻¹) or the same medium without the antibiotic for 48 h. Control experiments verified that *B. pertussis* remained alive in 10% FBS (DMEM), but not in 10%

---

**Fig. 6** Survival of *Bordetella pertussis* inside A549 cells in LAMP1-negative compartments. (a) Intracellular survival. A549 cells were infected with *B. pertussis* (MOI 150) for 2 h, washed to remove nonadherent bacteria, and incubated for a further 12 h. The cells were then treated with polymyxin B (100 μg mL⁻¹) for 1 h at 37 °C, washed, and incubated for an additional 0, 24, or 48 h in the presence of polymyxin B (5 μg mL⁻¹). The number of viable intracellular bacteria was evaluated at different times by CFU counts. The data represent the mean ± SD of four independent experiments each performed in triplicate. (b) Colocalization of *B. pertussis* and LAMP1. A549 cells were infected with GFP-*B. pertussis* (MOI 150) for 2 h, washed, and incubated for a further 12 h. Cells were then treated for 1 h with polymyxin B (100 μg mL⁻¹) and incubated for an additional 0, 24, or 48 h in the presence of the antibiotic. At the different time points, cells were fixed and permeabilized before incubation with antibodies against LAMP1 (red) and against *B. pertussis* (green). The bars indicate the number of LAMP1-positive (gray) or LAMP1-negative (black) phagosomes per cell. The data represent the mean of three independent experiments each performed in triplicate. (c) Representative confocal images showing colocalization of *B. pertussis* with LAMP1 at 48 h after polymyxin B treatment. Arrows indicate LAMP1-positive *B. pertussis* compartments.

**Fig. 7** Colocalization of *Bordetella pertussis* with early endosomal markers. A549 cells were infected with *B. pertussis* (MOI 150) during 2 h, washed, and incubated for other 12 h in 0.2% BSA (DMEM). Cells were then treated for 1 h with polymyxin B (100 μg mL⁻¹) and incubated for another 48 h in the presence of antibiotics. At 0, 24, and 48 h, the cells were fixed and permeabilized prior to incubation with antibodies against EEA1 (green) and against *B. pertussis* (red). The bars indicate percentages of EEA1-positive phagosomes. The data represent the mean ± SD of three independent experiments. Representative confocal microscopy images of the colocalization of *B. pertussis* with EEA1 48 h after polymyxin B treatment are shown. Arrows indicate EEA1-positive *B. pertussis* compartments.
FBS (DMEM) plus polymyxin B (5 μg mL⁻¹), indicating that the intracellular bacteria released into the medium would be able to survive only in the antibiotic-free medium. Samples were taken at 0, 24, and 48 h after initial polymyxin B treatment. The number of viable bacteria either cell-associated or free in the medium was determined under each condition tested (Fig. 8a and b, respectively). In samples taken at 24 and 48 h, a significantly higher number of viable bacteria both associated with the cell and free in the medium were found in the assays performed without antibiotics as compared with those containing antibiotics. These results suggested that intracellular *B. pertussis* was released in a viable state into the surrounding medium. Similar results were obtained in experiments carried out in 0.2% BSA (DMEM) or 1% FBS (DMEM); and because both of those media limited A549 cell growth during the 48-h infection period, the exiting from the cell by *B. pertussis* was very likely not associated with cell lysis as a consequence of culture overgrowth (data not shown).

**Discussion**

Bacterial pathogens are often divided into the categories of intracellular and extracellular microorganisms in accordance with their capacity to invade and survive within host cells. This division, however, has become increasingly blurred as more and more pathogens referred to historically as extracellular were found to have alternative intracellular lifestyles (Petersen & Krogfelt, 2003; Bower et al., 2005; Morey et al., 2011). In the example of *B. pertussis*, an increasing number of reports based on infection assays in cultured cells (Ewanowich et al., 1989; Friedman et al., 1992; Masure, 1993; Gueirard et al., 2005; Lamberti et al., 2008, 2010) and examination of biopsies (Bromberg et al., 1991; Hellwig et al., 1999; Paddock et al., 2008) have suggested that these bacteria are capable of invading many cell types. Recent research has further indicated that *B. pertussis* is able to evade intracellular killing (Lamberti et al., 2008, 2010). In particular, the bacterium has been demonstrated to be able to survive the encounter with immune cells so as to remain viable in nonacidic compartments with access to the recycling pathways (Lamberti et al., 2008, 2010). Moreover, *B. pertussis* seems able to replicate inside these compartments, suggesting that the species might be considered a facultative intracellular bacterium (Lamberti et al., 2010).

In the present study, we investigated the interaction of *B. pertussis* with respiratory epithelial cells, another relevant cell type at the site of infection. Several pathogens acquired through inhalation can invade respiratory epithelial cells, including *Mycoplasma pneumoniae* (Yavlovich et al., 2004), *Burkholderia cepacia* (Martin & Mohr, 2000), and *Haemophilus influenza* (Morey et al., 2011). Most of these invasive microorganisms, although not all, are also capable of intracellular replication. In the instance of *B. pertussis*, a number of studies, with both primary cell cultures and established cell lines, have suggested that this pathogen is able to invade epithelial cells (Higgs et al., 2012). The molecular mechanisms underlying this process and the intracellular fate of *B. pertussis*, however, have still remained unknown. The present study shows that the entry of *B. pertussis* into respiratory epithelial cells requires microtubule assembly, lipid raft integrity, and the activation of tyrosine kinases. Once inside the cell, a significant proportion of the bacteria evade lysosomal fusion and remain viable for several days.

We have previously shown that lipid raft domains act as platforms that cluster molecules susceptible to FHA ligation
and in that manner contribute to effective *B. pertussis* binding to A549 cells (Lamberti et al., 2009). These domains have been shown to be involved in cellular invasion by many pathogens (Lafont & van der Goot, 2005; Hartlova et al., 2010) and appear to provide the signaling platforms required for bacterial entry (Lafont & van der Goot, 2005; Zaas et al., 2005a). In the present experiments, we found that lipid rafts are involved in the entry of *B. pertussis* into respiratory epithelial cells. Accordingly, treatment of A549 cells with the lipid raft-disrupting drug M03CD decreased *B. pertussis* invasion to a greater extent than the reduction observed in attachment, suggesting that these domains not only serve as platforms that facilitate *B. pertussis* binding to the host cell, but also mediate the entry of the pathogen. Indeed, invasion by *B. pertussis* was significantly impaired in the presence of genistein, a selective inhibitor of tyrosine-kinase-mediated and lipid raft-dependent endocytotic pathways (Lajoie & Nabi, 2007), suggesting that tyrosine kinase activity is involved in *B. pertussis* internalization through lipid raft domains.

Lipid raft-dependent endocytosis may proceed through microtubule- and/or actin-dependent pathways (Lajoie & Nabi, 2007). Whereas actin microfilaments are frequently associated with the bacterial invasion process, a small number of pathogens need the polymerization of the host microtubule network to invade (Yoshida & Sasakawa, 2003). *Bordetella pertussis* seems to belong to this latter group of pathogens. Treatment of A549 cells with nocodazole, a microtubule-depolymerizing agent, significantly reduced the number of internalized bacteria. In contrast, actin–cytoskeleton depolymerization by cytochalasin D did not affect invasion by *B. pertussis*. Accordingly, intracellular *B. pertussis* was never found associated with condensed actin filaments.

*Bordetella pertussis* FHA plays a major role in adherence to epithelial cells (Perez Vidakovics et al., 2006). FHA has been suggested as possibly promoting the invasion of human respiratory epithelial cells through the interaction of the bacterial arginine–glycine–aspartate (RGD) sequence with the host cell α5β1 integrin (Ishibashi et al., 2001). Like *B. pertussis*, several microbial pathogens exploit integrins and the latter’s endocytotic capacity to invade nonphagocytic cells (Guignot et al., 2001; Tsuda et al., 2008; Krause–Gruszczynska et al., 2011; López-Gómez et al., 2012). The invasion of *Yersinia enterocolitica* has been demonstrated to involve the binding of the α5β1 integrins on eukaryotic cells in order to promote internalization via a receptor-mediated mechanism that, for its part, involves protein tyrosine kinase signaling (Isberg et al., 2000). These kinases are usually the orchestrators of a linkage between the integrins and signal transduction, with the lipid raft domains playing a key role in this interaction (Leitinger & Hogg, 2002; Mitchell et al., 2002; Gagnoux-Palacios et al., 2003; del Pozo et al., 2004; Upla et al., 2004; van Zanten et al., 2009). That lipid rafts and α5β1 integrins participate in *B. pertussis* entry into epithelial cells suggests a spatial and functional link between raft and integrins during *B. pertussis* entry.

A strategy used by several pathogens for survival in the hostile host environment is to hide within the mammalian cells. The mechanisms by which pathogens resist intracellular killing include inhibition of phagosome–lysosome fusion, escape into the cytoplasmic compartment, and resistance to the harsh environment of the lysosome (Moulder, 1985). To investigate the fate of *B. pertussis* inside respiratory cells, CFU counts and trafficking studies were conducted in parallel. We examined the association of *B. pertussis* with acidic (LysoTracker™-positive) vacuoles and LAMP1- and EEA1-containing vacuoles. Our overall data suggest that part of the internalized bacteria manage to avoid the lysosomal degradation pathway. We accordingly found a correlation between the number of viable intracellular bacteria and the number of either LAMP1-negative, LysoTracker™-negative, or EEA1-positive bacteria per cell, suggesting that those bacteria had survived through escape from the lysosomal pathway and remain in EEA1-positive compartments. These results are in agreement with previous reports indicating that *B. pertussis* is able to survive within nonacidic compartments in human macrophages (Lamberti et al., 2010).

Although we cannot rule out the possibility, under our experimental conditions, we did not detect bacterial replication inside A549 cells. A similar behavior had been found with other pathogens, such as *Campylobacter jejuni* (Watson & Galan, 2008), *B. cepacia* (Lamothe et al., 2004), and *Salmonella enterica* (Cano et al., 2001), all of which bacteria produce long-lasting infections inside host cells in the absence of proliferation.

Intracellular survival may provide substantial advantages for bacterial persistence within the host. Apart from protecting the pathogen from the host immunity defenses, the intracellular location detected here might provide protection against antibacterial treatments or local inflammation during infection. Similar to what was described for other pathogens (Osterlund & Engstrand, 1995; Dubois & Boren, 2007), *B. pertussis* might reside dormant inside host cells and egress once the extracellular environment became permissive. In this study, we found evidence that intracellular *B. pertussis* is able to repopulate the extracellular environment, with the implication that *B. pertussis* is released viable into the extracellular medium. These results suggest that the intracellular survival within the respiratory epithelium might contribute to the persistence of *B. pertussis* within the host.

Acknowledgements

This study was partially supported by a grant from UNLP and a grant from MIncYT–FONCyT PICT 0413. M.E.R. and Y.L. are members of the Scientific Career of the CONICET. J.G. is a doctoral fellow of the CONICET.

References


Friedman and dynamic unstable microtubules. subsequent Internalization through a pathway involving caveolae epithelial cells: evidence for alpha5beta1 integrin recognition and Diffusely Adhering


